The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea-Reference-Cited by-同舟云学术

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea

Published:2015-08-27 Issue:5 Volume:30 Page:675-683
ISSN:1226-3303
Container-title:The Korean Journal of Internal Medicine
language:en
Short-container-title:Korean J Intern Med

Author:

Kim Cheolsu,Lee Ho Sup,Min Chang-Ki,Lee Je Jung,Kim Kihyun,Yoon Dok Hyun,Eom Hyeon Seok,Lee Hyewon,Lee Won Sik,Shin Ho-Jin,Lee Ji Hyun,Park Yong,Jo Jae-Cheol,Do Young Rok,Mun Yeung-Chul

Funder

Kosin University College of Medicine

Publisher

Korean Association of Internal Medicine

Link

http://kjim.org/upload/kjim-30-5-675.pdf

Reference29 articles.

1. Thalidomide for treatment of multiple myeloma: 10 years later

2. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

3. Role of thalidomide in the treatment of patients with multiple myeloma

4. Initial Treatment of Transplant Candidates With Multiple Myeloma

5. Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamic monitoring of serum ferritin as an adverse prognostic biomarker in patients with multiple myeloma;Biomarkers in Medicine;2021-11

2. Recent advances in multiple myeloma: a Korean perspective;The Korean Journal of Internal Medicine;2016-09-01